Global Cancer Biopsy Market Size Study by Type, Application, Product, and Regional Forecasts 2022-2032

Description

The Global Cancer Biopsy Market, valued at approximately USD 30.05 billion in 2023, is poised to ascend to a staggering USD 60.62 billion by 2032, showcasing a robust compound annual growth rate (CAGR) of 8.11% during the forecast period from 2024 to 2032. This remarkable growth trajectory is underpinned by the escalating demand for non-invasive diagnostic tools and the rising prevalence of cancer worldwide. Cancer biopsy techniques, such as liquid biopsies and core needle biopsies, have revolutionized oncology by enabling precise, early-stage cancer detection and facilitating personalized treatment approaches.

Liquid biopsies, celebrated for their minimally invasive nature, have gained substantial traction in recent years. These innovative diagnostic tools, capable of detecting circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in blood, offer clinicians a dynamic and comprehensive view of the tumor's molecular landscape. Complementing this, core needle biopsies remain a gold standard for obtaining tissue samples in cases where detailed histopathological analysis is required. Together, these techniques are redefining the paradigm of cancer diagnosis and monitoring, empowering healthcare professionals to make informed clinical decisions.

The market's growth is further propelled by technological advancements in biopsy instruments and kits, which have enhanced the accuracy, efficiency, and patient comfort associated with cancer diagnosis. Investments in R&D by leading market players, coupled with supportive government initiatives aimed at bolstering cancer screening programs, are significantly contributing to the market's expansion. However, high procedural costs and limited access to advanced biopsy technologies in emerging economies remain key challenges.

Regionally, North America dominates the Cancer Biopsy Market, driven by its robust healthcare infrastructure, significant investments in cancer research, and widespread adoption of advanced diagnostic tools. Europe follows suit, with strong government support and an increasing focus on early detection and precision medicine. The Asia Pacific region is anticipated to witness the fastest growth, fueled by rising healthcare expenditure, improving cancer awareness, and the burgeoning adoption of innovative diagnostic technologies in countries like China and India. Meanwhile, Latin America and the Middle East & Africa present lucrative opportunities, underpinned by improving healthcare access and rising investments in oncology diagnostics.

Major market players included in this report are:

QIAGEN
Thermo Fisher Scientific
Biocept, Inc.
Guardant Health, Inc.
Roche Diagnostics
Illumina, Inc.
Bio-Rad Laboratories
Myriad Genetics, Inc.
Agilent Technologies
F. Hoffmann-La Roche Ltd
Menarini Silicon Biosystems
Genomic Health
Hologic, Inc.
Sysmex Corporation
Oxford Gene Technology

The detailed segments and sub-segments of the market are explained below:

By Type:

Liquid Biopsy
Core Needle Biopsy

By Application:

Breast Cancer
Lung Cancer

By Product:

Kits & Consumables
Instruments

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America:

Brazil
Mexico
Rest of Latin America

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Comprehensive analysis of the geographical landscape with country-level insights across major regions.
Competitive landscape featuring detailed profiles and strategies of major market players.
Analysis of key business strategies and recommendations for future market approaches.
Comprehensive analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Cancer Biopsy Market Executive Summary 1.1. Global Cancer Biopsy Market Size & Forecast (2022-2032)

1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Cancer Biopsy Market Definition and Research Assumptions 2.1. Research Objective

2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Cancer Biopsy Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Cancer Worldwide
- 3.1.2. Increase in Demand for Non-Invasive Diagnostic Tools
- 3.1.3. Technological Advancements in Biopsy Techniques
3.2. Market Challenges
- 3.2.1. High Procedural Costs
- 3.2.2. Limited Access to Advanced Biopsy Technologies in Emerging Economies
3.3. Market Opportunities
- 3.3.1. Growing Adoption of Liquid Biopsies
- 3.3.2. Expanding Healthcare Infrastructure in Emerging Markets
- 3.3.3. Increase in Investments in Oncology Diagnostics

Chapter 4. Global Cancer Biopsy Market Industry Analysis 4.1. Porter's 5 Force Model

4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Biopsy Market Size & Forecasts by Type 2022-2032 5.1. Segment Dashboard

5.2. Global Cancer Biopsy Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Liquid Biopsy
- 5.2.2. Core Needle Biopsy

Chapter 6. Global Cancer Biopsy Market Size & Forecasts by Application 2022-2032 6.1. Segment Dashboard

6.2. Global Cancer Biopsy Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Breast Cancer
- 6.2.2. Lung Cancer

Chapter 7. Global Cancer Biopsy Market Size & Forecasts by Product 2022-2032 7.1. Segment Dashboard

7.2. Global Cancer Biopsy Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Kits & Consumables
- 7.2.2. Instruments

Chapter 8. Global Cancer Biopsy Market Size & Forecasts by Region 2022-2032 7.1. North America Cancer Biopsy Market

7.1.1. U.S. Cancer Biopsy Market
- 7.1.1.1. Liquid Biopsy Breakdown Size & Forecasts, 2022-2032
- 7.1.1.2. Core Needle Biopsy Breakdown Size & Forecasts, 2022-2032
7.1.2. Canada Cancer Biopsy Market
- 7.1.2.1. Liquid Biopsy Breakdown Size & Forecasts, 2022-2032
- 7.1.2.2. Core Needle Biopsy Breakdown Size & Forecasts, 2022-2032

7.2. Europe Cancer Biopsy Market
- 7.2.1. U.K. Cancer Biopsy Market
- 7.2.2. Germany Cancer Biopsy Market
- 7.2.3. France Cancer Biopsy Market
- 7.2.4. Spain Cancer Biopsy Market
- 7.2.5. Italy Cancer Biopsy Market
- &; 7.2.6. Rest of Europe Cancer Biopsy Market
7.3. Asia-Pacific Cancer Biopsy Market
- 7.3.1. China Cancer Biopsy Market
- 7.3.2. India Cancer Biopsy Market
- 7.3.3. Japan Cancer Biopsy Market
- 7.3.4. Australia Cancer Biopsy Market
- 7.3.5. South Korea Cancer Biopsy Market
- 7.3.6. Rest of Asia Pacific Cancer Biopsy Market
7.4. Latin America Cancer Biopsy Market
- 7.4.1. Brazil Cancer Biopsy Market
- 7.4.2. Mexico Cancer Biopsy Market
- 7.4.3. Rest of Latin America Cancer Biopsy Market
7.5. Middle East & Africa Cancer Biopsy Market
- 7.5.1. Saudi Arabia Cancer Biopsy Market
- 7.5.2. South Africa Cancer Biopsy Market
- 7.5.3. Rest of Middle East & Africa Cancer Biopsy Market

Chapter 8. Competitive Intelligence 8.1. Key Company SWOT Analysis

8.1.1. QIAGEN
8.1.2. Thermo Fisher Scientific
8.1.3. Biocept, Inc.

8.2. Top Market Strategies
8.3. Company Profiles
- 8.3.1. QIAGEN
  - 8.3.1.1. Key Information
  - 8.3.1.2. Overview
  - 8.3.1.3. Financial (Subject to Data Availability)
  - 8.3.1.4. Product Summary
  - 8.3.1.5. Market Strategies
- 8.3.2. Thermo Fisher Scientific
- &; 8.3.3. Biocept, Inc.
- 8.3.4. Guardant Health, Inc.
- 8.3.5. Roche Diagnostics
- 8.3.6. Illumina, Inc.
- 8.3.7. Bio-Rad Laboratories
- 8.3.8. Myriad Genetics, Inc.
- 8.3.9. Agilent Technologies
- 8.3.10. F. Hoffmann-La Roche Ltd

Chapter 9. Research Process 9.1. Research Process

9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing

9.2. Research Attributes